✦ LIBER ✦

P201 High-dose therapy and autologous transplantation in poor prognosis patients with diffuse large B-cell lymphoma in first remission

✍ Scribed by T. Papajik; L. Raida; E. Faber; V. Prochazka; J. Vondrakova; I. Skoumalova; Z. Kubova; M. Jarosova; J. Jarkovský; L. Dusek; K. Indrak

Book ID: 104323090
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 48 KB
Volume: 21
Category: Article
ISSN: 0268-960X
DOI: 10.1016/s0268-960x(07)70097-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Perforation predicts poor prognosis in p

Perforation predicts poor prognosis in patients with primary intestinal diffuse large B-cell lymphoma

✍ S-S Chuang; H Ye; S-F Yang; W-T Huang; H-K Chen; P-P Hsieh; W-S Hwang; K-Y Chang 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 384 KB

Cryofibrinogenemia and skin necrosis in

Cryofibrinogenemia and skin necrosis in a patient with diffuse large cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation

✍ Shimoni, A; Körbling, M; Champlin, R; Molldrem, J 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 73 KB

Chemotherapy with rituximab followed by

Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma

✍ Catherine Thieblemont; Daciana Antal; Laurence Lacotte-Thierry; Vincent Delwail; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

## Abstract ## BACKGROUND The authors evaluated the efficacy of chemotherapy combined with rituximab followed by high‐dose therapy (HDT) plus autologous stem cell transplantation in patients with mantle cell lymphoma (MCL). ## METHODS This was a retrospective analysis of 34 patients who were tre

Should Eligible Patients with T-Cell Lym

Should Eligible Patients with T-Cell Lymphoma Receive High-Dose Therapy and Autologous Stem Cell Transplant in the Upfront Setting?

✍ Carla Casulo; Steven Horwitz 📂 Article 📅 2010 🏛 Current Science Inc. 🌐 English ⚖ 166 KB

P009 “High-risk” patients with aggressiv

P009 “High-risk” patients with aggressive non-Hodgkin lymphoma should benefit from autologous stem cell transplantation in first remission (single-centre experience)

✍ S. Genadieva Stavrik; L. Cevreska; Z. Stojanoski; A. Pivkova; A. Stojanovik; S. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Therapeutic results in patients with rel

Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation

✍ Felicetto Ferrara; Assunta Viola; Carolina Copia; Ettore Mariano Schiavone; Mari 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

## Abstract Forty patients with relapsed diffuse large B cell lymphoma (DLBCL) autografted in partial response (PR) (__n__ = 23) or in refractory relapse (RR) (__n__ = 17) achieved complete remission (CR) after autologous stem cell transplantation (ASCT). Salvage treatment consisted of ifosphamide,